AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Madrigal on 7/23 was $117.10 Million, Ranking 808
ByAinvest
Wednesday, Jul 23, 2025 6:20 pm ET1min read
The turnover of Madrigal on 7/23/2025 was $117.10 million, ranking 808 in today's market, the Volume is 0.38 million.
Madrigal(MDGL) shares closed at $306.76, down 2.12% on 7/23/2025, down 11.08% in the last 5 trading days, up 1.36% this month, down 0.59% year-to-date and up 8.76% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 7/23/2025 | $117.10 million | 0.38 million | $306.76 | -2.12% |
| 7/22/2025 | $184.87 million | 0.58 million | $313.4 | -5.30% |
| 7/21/2025 | $76.85 million | 0.23 million | $330.94 | -0.95% |
| 7/18/2025 | $109.83 million | 0.33 million | $334.13 | -4.19% |
| 7/17/2025 | $126.17 million | 0.36 million | $348.73 | 1.09% |
【Company Profile】
Madrigal Pharmaceuticals, Inc. was incorporated in March 2000 and commenced operations in July 2001.
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical stage of development. All of the company's drug candidates have been discovered and developed internally using the company's proprietary, unique chemical compound library and integrated discovery engine. The company retains full ownership of all of its drug candidates.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet